Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study

Not Applicable

Withdrawn

• Conditions: Hypertension
• Interventions: Drug: Lisinopril, Atenolol

• Registration Number: NCT01009944
• Lead Sponsor: Brigham and Women's Hospital

Brief Summary

The purpose of this study is to develop an approach to provide personalized medicine to individuals who have hypertension (high blood pressure). The investigators plan to use people's genetic characteristics (traits) to determine what medication they should use to lower their blood pressure most effectively. The investigators will give individuals one of two medications to treat hypertension (lisinopril or atenolol). The investigators believe that depending on the individuals genetic background one medication will work better in lowering their blood pressure.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-01
• Study First Submitted: 2009-11-06
• Study First Submitted QC: 2009-11-06
• Study First Posted: 2009-11-09
• Primary Completion: 2019-03-19
• Study Completion: 2019-03-19
• Status Verified: 2021-04
• Last Update Submitted: 2021-04-07
• Last Update Posted: 2021-04-09

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Male and female hypertensive participants who were previously studied in SCOR program.

Exclusion Criteria

• Diabetes
• Taking other medications beside thyroid or estrogen supplements.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Lisinopril, Atenolol	Lisinopril, Atenolol	-

Primary Outcome Measures

Name	Time	Method
One type of blood pressure medication will better treat individuals with certain genetic backgrounds.	16 weeks

Trial Locations

Locations (1)

Brigham and Women's Hospital; 🇺🇸 Boston, Massachusetts, United States